9.8.14 | The Life Sciences Report
When Steve Brozak performs diligence on biotech stocks, he’s always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms and novel ideas fit into tomorrow’s healthcare system, which he believes will be unsustainable without therapies that work more efficiently and hold promise as true disease-modifying agents. In this interview with The Life Sciences Report, Brozak brings eight names to investors’ attention. For the full article, please click here.
